DIFFERENCES BETWEEN THE SUGAR MOIETIES OF LIVER-TYPE AND BONE-TYPE ALKALINE-PHOSPHATASES - A REEVALUATION

被引:25
作者
MIURA, M [1 ]
SAKAGISHI, Y [1 ]
HATA, K [1 ]
KOMODA, T [1 ]
机构
[1] MITSUBISHI YUKA BIOCLIN LABS INC,DEPT RES & DEV,ITABASHI KU,TOKYO,TOKYO 174,JAPAN
关键词
SIALYLATION; SIALYLTRANSFERASE; NEURAMINIDASE; O-GLYCANASE; ANTIGENICITY; MOLECULAR SIZE;
D O I
10.1177/000456329403100104
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
We re-evaluated the differences between the sugar moieties of liver and bone alkaline phosphatases (ALPs). Sialic acid was added to ALP sugar moieties by alpha 2,3- or 2,6-sialyltransferase treatment of the asialo-form ALP (neuraminidase-treated ALP). Asialo-bone ALP was converted to a liver-like ALP by the 2,6-sialyltransferase treatment. The resulting liver-like ALP was less susceptible to neuraminidase than non-treated bone ALP, but was still labile to heat exposure at 56 degrees C like non-treated bone ALP. However, after the O-linked sugar moiety had been released by additional treatment with O-glycanase the liver-like ALP became more heat stable at 56 degrees C, like non-treated liver ALP. Non-treated liver ALP reacted specifically with anti-liver ALP monoclonal antibody, and non-treated bone ALP reacted with both anti-liver and anti-bone ALP antibodies. The asialo-bone ALP still reacted with anti-bone ALP antibody, whereas the asialo-form liver ALP showed little, if any, reaction with anti-liver and anti-bone ALP antibodies. Neuraminidase and O-glycanase-treated bone ALP reacted less with anti-bone ALP antibody. After O-glycanase treatment, bone ALP molecules deprived of an O-linked sugar moiety had a molecular size and heat stability similar to liver ALP. The difference between liver and bone ALP molecules may be due not only to their manner of sialic acid linkage but also to the attachment of the O-linked sugar moiety.
引用
收藏
页码:25 / 30
页数:6
相关论文
共 27 条
[1]  
ANDERSON DJ, 1990, CLIN CHEM, V36, P240
[2]   THE PREPARATION OF MONOCLONAL-ANTIBODIES TO HUMAN-BONE AND LIVER ALKALINE-PHOSPHATASE AND THEIR USE IN IMMUNOAFFINITY PURIFICATION AND IN STUDYING THESE ENZYMES WHEN PRESENT IN SERUM [J].
BAILYES, EM ;
SEABROOK, RN ;
CALVIN, J ;
MAGUIRE, GA ;
PRICE, CP ;
SIDDLE, K ;
LUZIO, JP .
BIOCHEMICAL JOURNAL, 1987, 244 (03) :725-733
[3]   HYPERPHOSPHATASEMIA RELATED TO 3 INTESTINAL ALKALINE-PHOSPHATASE ISOFORMS - BIOCHEMICAL-STUDY [J].
BENTOUATI, L ;
BABOLI, MS ;
HACHEM, H ;
HAMZA, M ;
CANAL, P ;
SOULA, G .
CLINICA CHIMICA ACTA, 1990, 193 (1-2) :93-102
[4]   A SIMPLE ELECTROPHORETIC METHOD FOR SEPARATING ELEVATED LIVER AND BONE ALKALINE-PHOSPHATASE ISOENZYMES IN PLASMA AFTER NEURAMINIDASE TREATMENT [J].
CHAMBERLAIN, BR ;
BUTTERY, JE ;
PANNALL, PR .
CLINICA CHIMICA ACTA, 1992, 208 (03) :219-224
[5]   THE RELEASE OF N-ACETYLNEURAMINIC AND N-GLYCOLLOYL-NEURAMINIC ACID FROM SOLUBLE COMPLEX CARBOHYDRATES AND ERYTHROCYTES BY BACTERIAL, VIRAL AND MAMMALIAN SIALIDASES [J].
CORFIELD, AP ;
VEH, RW ;
WEMBER, M ;
MICHALSKI, JC ;
SCHAUER, R .
BIOCHEMICAL JOURNAL, 1981, 197 (02) :293-299
[6]   IMMUNOLOGICAL STUDY ON HYPOPHOSPHATASIA [J].
GOSEKI, M ;
OIDA, S ;
TAKAGI, Y ;
OKUYAMA, T ;
WATANABE, J ;
SASAKI, S .
CLINICA CHIMICA ACTA, 1990, 190 (03) :263-268
[7]  
GRIFFITHS J, 1989, PROG CLIN BIOCH MED, V8, P63
[8]   CERTAIN NEUROLEPTICS REDUCE BONE MINERALIZATION IN SCHIZOPHRENIC-PATIENTS [J].
HIGUCHI, T ;
KOMODA, T ;
SUGISHITA, M ;
YAMAZAKI, J ;
MIURA, M ;
SAKAGISHI, Y ;
YAMAUCHI, T .
NEUROPSYCHOBIOLOGY, 1987, 18 (04) :185-188
[9]   INTESTINAL-LIKE ALKALINE-PHOSPHATASE EXPRESSED IN NORMAL HUMAN ADULT KIDNEY [J].
HIRANO, K ;
KUSANO, K ;
MATSUMOTO, Y ;
STIGBRAND, T ;
IINO, S ;
HAYASHI, K .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1989, 183 (02) :419-423
[10]   HISTOCHEMICAL, ULTRACYTOCHEMICAL AND BIOCHEMICAL-STUDY OF ALKALINE-PHOSPHATASE ACTIVITY DURING GASTRIC CARCINOGENESIS [J].
HIROTA, N ;
SAKAI, T ;
KOMODA, T .
CLINICA CHIMICA ACTA, 1990, 186 (02) :301-307